Good morning :)
$
₹
Lyra Therapeutics Inc

Lyra Therapeutics Inc

LYRA

NASDAQ
Asset Logo

Lyra Therapeutics Inc

LYRA

NASDAQ
$2.320.85% (-0.02)
$
₹
$2.320.85% (-0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Unknown

Sector and industry information not available

Micro Cap

With a market cap of $878.6k the stock is ranked 6199

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.90
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-22.9
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 4 analysts' reports

Buy
0 analyst
Hold
4 analysts
Sell
0 analyst

Analysts expect a +3100.00% price upside over the next year

Current Price$2.32
Target Price$16

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.42
72.42
1Y Return
21.16%
21.16%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.42
23.42
1Y Return
37.87%
37.87%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.99%
29.99%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.03
30.03
1Y Return
30.87%
30.87%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.34
19.34
1Y Return
35.36%
35.36%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Lyra Therapeutics Inc -3.90-
AbbVie Inc72.4250.450.52
Amgen Inc23.4217.452.27

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Frequently asked questions

Frequently asked questions

  1. Lyra Therapeutics Inc (LYRA) share price today is $2.31 as of January 21, 2026 at 10:43 PM IST. The stock touched a day high of $0.00 and a day low of $0.00.

  2. Lyra Therapeutics Inc stock trades on NASDAQ under the ticker symbol LYRA.

  3. Lyra Therapeutics Inc's market capitalization is $878.6K as of January 21, 2026 at 10:43 PM IST.

  4. Lyra Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of September 15, 2026.

  5. Lyra Therapeutics Inc's price-to-book (P/B) ratio is 3.90 as of September 15, 2026.

  6. Yes, You can buy Lyra Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Lyra Therapeutics Inc shares in three steps: 1. Search Lyra Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Lyra Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Lyra Therapeutics Inc (LYRA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.3103 shares at the current price of $2.31.

Loading...